EMEA-002310-PIP02-17
Key facts
| Active substance |
(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4- fluoropyrrolidine-2-carboxamide (ACH-0144471)
|
| Therapeutic area |
Uro-nephrology
|
| Decision number |
P/0243/2019
|
| PIP number |
EMEA-002310-PIP02-17
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of C3 glomerulopathy
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Achillion Pharmaceuticals, Inc.
Tel.+1 203 624 7000 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|